Indian Patients with Diabetes Experienced Better Glycemic Control, Less Weight Gain and Hypoglycaemia with Insulin. Detemir When Switched from NPH and Insulin Glargine in PREDICTIVE™ Study

被引：0

作者：

Kesavadev, Jothydev

Singh, Parminder

Pitle, Shailesh Umakant

Bhttacharyya, Arpandev

Mayya, Raghavendra

Moharana, Ashok Kumar

Pathak, Ankit

Kalra, Sanjay

机构：

来源：

DIABETES | 2009年 / 58卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：A528 / A528

页数：1

共 50 条

[21] Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia:: 14-week follow-up data from PREDICTIVE™
Dornhorst, A.
Lueddeke, H.-J.
Koenen, C.
Merilainen, M.
King, A.
Robinson, A.
Sreenan, S.
DIABETES OBESITY & METABOLISM, 2008, 10 (01): : 75 - 81
[22] Glargine Utilization in Russia: A Retrospective Comparative Study To Evaluate Patients Switched from NPH Insulin to Insulin Glargine Compared with Patients Maintained on NPH
Jarek-Martynowa, Iwona
Shamkhalova, Minara
Shestakova, Marina
DIABETES, 2011, 60 : A608 - A608
[23] Decreased hypoglycaemic episodes and less weight gain in patients with Type 1 diabetes transferred from NPH to insulin glargine with maintenance of glycaemic control despite lower insulin doses
Gottlieb, R
Garg, S
Paul, J
Chase, P
Menditto, L
DIABETOLOGIA, 2004, 47 : A304 - A304
[24] Insulin detemir results in less weight gain than NPH insulin when added to oral agents in type 2 diabetes, with this advantage increasing with baseline obesity
Hermansen, K
Tamer, SC
DIABETOLOGIA, 2005, 48 : A4 - A5
[25] The advantage of less weight gain increases with baseline obesity when insulin detemir rather than NPH insulin is added to oral agents in type 2 diabetes
Hermansen, K
Tamer, SC
DIABETES, 2005, 54 : A67 - A67
[26] Insulin Detemir Improves Glycemic Control with Boner Tolerability and No Weight Gain in Patients with Type 1 or Type 2 Diabetes: 26 Week Data from the Indian Cohort of PREDICTIVE™ Study
Ramachandran, Ambady
Patwardhan, Milind
Asirvatham, Arthur Joseph
Moharana, Ashok Kumar
Pathak, Ankit
Saikia, Mihir
DIABETES, 2009, 58 : A529 - A529
[27] Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE™ study in a cohort of French patients with type 1 or type 2 diabetes
Marre, M.
Pinget, M.
Gin, H.
Thivolet, C.
Hanaire, H.
Robert, J. -J.
Fontaine, P.
DIABETES & METABOLISM, 2009, 35 (06) : 469 - 475
[28] GLARGINE UTILISATION IN RUSSIA: A PROSPECTIVE STUDY TO EVALUATE PATIENTS SWITCHED FROM NPH INSULIN TO INSULIN GLARGINE COMPARED WITH THOSE MAINTAINED ON NPH
Skudaev, S.
Verbovaya, N.
VALUE IN HEALTH, 2011, 14 (07) : A473 - A473
[29] Treatment with insulin detemir in combination with oral agents is associated with less risk of hypoglycaemia and less weight gain than NPH insulin at comparable levels of glycaemic improvement in people with Type 2 diabetes
Hermansen, K
Derezinski, T
Kim, H
Gall, MA
DIABETOLOGIA, 2004, 47 : A273 - A274
[30] Once-daily insulin detemir added to oral antidiabetic drugs results in less weight gain and a trend for reduced hypoglycaemia in comparison to NPH insulin in Japanese patients with type 2 diabetes
Tajima, N.
Iwamoto, Y.
Kaku, K.
Kawamori, R.
Nishida, T.
Kobayashi, M.
DIABETOLOGIA, 2006, 49 : 609 - 609

← 1 2 3 4 5 →